News
December 16, 2014

Legal Considerations For Pharmaceutical Brand Protection Programs

Bloomberg BNA's Pharmaceutical Law & Industry Report

By Ryan D. Guilds E. Alex Beroukhim
Find more content tagged:

People

Ryan D. Guilds
Ryan D. Guilds
Counsel
Washington, DC
+1 202.942.6188
Email
VCard
E. Alex Beroukhim
E. Alex Beroukhim
Partner
Los Angeles
+1 213.243.4059
Email
VCard

Related Content

July 31, 2020
Update: Regulation for COVID-19 clinical trials conducted with medicinal products containing or consisting of GMOs has now been adopted
BioSlice Blog
Subscribe
Subscribe Link

Email Disclaimer

Reject Accept